FREED of Opioids Act

This bill directs the FDA to review a specific clinical trial method (enriched enrollment randomized withdrawal) used in testing opioid drugs for chronic pain. Within two years, the FDA must convene advisory committees to decide whether to permit this method, while also commissioning a National Academy of Sciences study on its effectiveness. The bill further requires the FDA to review the labeling of all opioid drugs approved using this method to ensure their pain treatment claims are supported by the evidence. These changes primarily affect the FDA's drug review process and pharmaceutical companies developing opioid medications, with no direct impact on patients or healthcare providers.